Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease

Journal of Thoracic Disease

Volumn 5, Issue 6, 2013, Pages 806-814

  Seth, Heemesh D ^a   Sultan, Samir ^a   Gotfried, Mark H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease (COPD); Formoterol; Indacaterol; Long acting beta2 agonist ( 2 agonist); Salmeterol; Tiotropium

Indexed keywords

FORMOTEROL; INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ANXIETY DISORDER; BACKACHE; BETA ADRENERGIC STIMULATION; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEADACHE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG FUNCTION TEST; PRACTICE GUIDELINE; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 84892420663     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2013.10.11     Document Type: Review

References (33)

1. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-56.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73.
3. Ford ES, Croft JB, Mannino DM, et al. COPD surveillance--United States, 1999-2011. Chest 2013;144:284-305.
4. Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis 2013;8:117-25.
5. Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis 2012;7:145-52.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. Available online: http://www.goldcopd.org/Guidelines/guidelines-resources.html
7. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41.
8. Cazzola M, Page CP, Rogliani P, et al. ß2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6.
9. Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011;12:40.
10. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting ß2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011;140:68-75.
11. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030-6.
12. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res 2010;11:79.
13. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
14. Taube C, Lehnigk B, Paasch K, et al. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:216-20.
15. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med 2005;171:591-7.
16. Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adv Exp Med Biol 2013;756:23-8.
17. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
18. Jiang FM, Liang ZA, Zheng QL, et al. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung 2013;191:135-46.
19. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92.
20. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
21. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011;11:31.
22. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797-803.
23. Kornmann O, Dahl R, Centanni S, et al.Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9.
24. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
25. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8.
26. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting ß-agonists for stable COPD: a systematic review. Chest 2012;142:1104-10.
27. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71.
28. Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol--the FDA's review. N Engl J Med 2011;365:2247-9.
29. Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther 2011;33:1974-84.
30. Gotfried MH, Kerwin EM, Lawrence D, et al. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. COPD 2012;9:629-36.
31. Cope S, Kraemer M, Zhang J, et al. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2012;7:415-20.
32. Cope S, Zhang J, Williams J, et al. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med 2012;12:29.
33. Rutten-van Mölken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271-302.